Dr. Philip Krause to Provide Strategic Advice to Adjuvance
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio. Dr. Krause recently served as the Deputy Director, Office of Vaccines Research and Review of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research.
“The deep scientific, regulatory and vaccine development experience that Phil brings to Adjuvance will be instrumental in efficiently developing our shingles vaccine candidate and our pipeline anchored on the next-generation saponin adjuvant TQL-1055,” noted Dr. Tyler Martin, Adjuvance CEO, President and Chairman. “I am thrilled to enhance the company’s expertise with such a well-respected scientist.”
Dr. Krause previously had a 30-year career in the FDA where he made major contributions in design of clinical trials, molecular virology and immunology, and the regulation and development of vaccines. He will provide strategic consulting on vaccine development, US and international regulatory affairs, clinical trial design and evaluation, virology and immunology and global health.
Dr. Krause said, “I look forward to this opportunity to provide advice and counsel to the Adjuvance leadership team on the development of their innovative saponin adjuvant platform, and their lead vaccine candidates.”
About TQL-1055: TQL-1055 is a rationally designed, semi-synthetic analogue of the QS-21 saponin adjuvant, which is used in the currently available shingles vaccine. Saponin adjuvants are potent immune stimulators and important components of licensed, currently marketed, and clinically advanced infectious disease vaccines. The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. TQL-1055 is designed to have improved tolerability and to provide the same strong immune response as QS21 and has shown favorable tolerability in a Phase 1 clinical trial. Adjuvance is designing new combination adjuvants, with TQL-1055 as the foundation, to produce different types of immune responses.
About Shingles: Shingles (also known as herpes zoster) is a painful rash that develops, often on the face or torso, and has the potential complication of pain that can last for months or even years. Vaccination against shingles is recommended in the United States and many countries for older adults and people with weak immune systems, resulting in a market value of over $2.0 billion in 2020. Available shingles vaccines contain the saponin adjuvant QS-21 and the toll-like receptor (TLR) 4 agonist adjuvant monophosphoryl lipid A (MPL), known together as the AS01 adjuvant. The adjuvanted shingles vaccine is highly effective, but can cause short-term adverse events more intense than other vaccines. About 1 out of 6 people who got the available shingles vaccine experienced side effects that prevented them from doing regular activities. Symptoms went away on their own in about 2 to 3 days.
About Adjuvance Technologies: Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our lead vaccine candidate against shingles aims to provide a better patient experience including improved tolerability for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institutes of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005493/en/
Contact information
Adjuvance:
Media
Howard Matzner
Senior Account Executive
LaVoieHealthScience
hmatzner@lavoiehealthscience.com
+1 617-865-0048
Investors
Tyler Martin
Chief Executive Officer
+1 402-817-5050
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTIMindtree Secures $450 Million Multi-Year Deal with Global Agribusiness Leader12.5.2025 11:30:00 EEST | Press release
LTIMindtree[NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, today announced a strategic agreement with a leader in the global agribusiness sector. This is the largest deal in the history of LTIMindtree, valued at $450 million across seven years. As a part of this deal, LTIMindtree will implement an AI-powered operating model to deliver application management, infrastructure support, and cybersecurity services. This comprehensive suite of future-ready IT services, built on platforms such as SAP S/4HANA, ServiceNow, Microsoft Azure, as well as proprietary AI frameworks, are aimed at enhancing the client’s operational efficiency, scalability, and global growth. "Securing this large deal marks a pivotal milestone as we transform to an AI-driven business model, helping our clients enhance productivity," said Venu Lambu, Chief Executive Officer (Designate) and Whole-Time Director, LTIMindtree. "We are proud to be the trusted partner for one of the world
KCx Integrates Proprietary Data into FlexTrade’s AI Assistant, FlxAI12.5.2025 11:04:00 EEST | Press release
FlexTrade Systems, a global leader in multi-asset execution and order management systems, and Kepler Cheuvreux, a leading independent European financial services company through its KCx execution services, today announced the availability of KCx’s sophisticated analytical suite directly from FlexTrade’s AI assistant, FlxAI, to deliver intelligent, high-value insights into client workflows. With rapid advancements in AI, large language models are reshaping how financial firms interact with data. Trading desks are increasingly embracing conversational AI to streamline decision-making and extract actionable insights faster than ever before. In response to market drivers, the new workflow has been developed as part of a collaborative initiative between KCx’s and FlexTrade’s teams. Through the new collaboration, users of FlxAI, which is seamlessly embedded in FlexTrade's FlexONE OEMS and FlexTRADER EMS solutions, can actively query KCx liquidity drivers through natural language commands, su
Shin-Etsu Chemical Develops New Silicone Products for Personal Care Use That Will Improve Texture and Functionality in Cosmetics12.5.2025 09:30:00 EEST | Press release
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) has developed new silicone products for personal care applications as part of its silicon chemistry-driven solutions (Shin-Etsu Silicones Solution-EngineeringTM). In the personal care industry, research and development activities are being carried out on various themes such as addressing diverse consumer demand and environmental issues and improving production efficiency. In response to these needs, Shin-Etsu Chemical has added new products to its lineup. [New Products] KF-6070W and KF-6080W are silicones in which some of the methyl groups in the molecular structure of dimethyl silicone oil (INCI name: dimethicone) have been replaced with hydrophilic functional groups. Both products combine high affinity with water due to their hydrophilic functional groups, while also imparting the excellent characteristics of silicone—high fluidity and smooth, non-sticky feel—to cosmetics
Cooler Master Launches Hyper 612 APEX: Compact, High-Performance CPU Cooler for Modern Builds12.5.2025 09:05:00 EEST | Press release
Cooler Master, a global leader in PC components and tech lifestyle solutions, today unveiled the Hyper 612 APEX, an all-new CPU air cooler engineered for users who demand cutting-edge thermal performance in a streamlined footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250511858017/en/ Cooler Master Hyper 612 APEX air cooler Featuring in-house developed superconductive composite heat pipes and the high-powered Mobius 120P fan, the Hyper 612 APEX delivers exceptional cooling efficiency while being 30% smaller than its predecessor, ensuring enhanced compatibility with large memory modules and tighter system builds. Ideal for gamers, content creators, and overclockers, the Hyper 612 APEX is meticulously designed to balance elite performance, user-friendly installation, and sleek aesthetics. “The Hyper 612 APEX is designed to meet the needs of users who want efficient cooling without the bulk,” said Jimmy Sha, Cooler Ma
Zeon and Sino Applied Technology Join Hands to Expand Single-Walled Carbon Nanotube Conductive Paste Product Line and Promote the Application of Next-Generation Lithium Batteries in Electric Vehicles12.5.2025 09:00:00 EEST | Press release
Zeon Corporation (Zeon) and Sino Applied Technology (SiAT) are thrilled to announce the signing of a strategic partnership in Taoyuan, Taiwan. As part of this collaboration, Zeon will lead a $20 million USD Series C fundraising round in SiAT to support the expansion of its production capacity for single-walled carbon nanotube (SWCNT) conductive paste, a critical nanomaterial for next-generation battery technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250511242604/en/ ZEONANO®, Single-Walled Carbon Nanotube produced by Zeon Super Growth Method The global demand for lithium-ion batteries is surging across consumer applications—such as electric vehicles, drones, and EVTOL aircraft—as well as industrial sectors, including AI server BBUs, renewable energy ESS, and automated robotics. This growth has intensified the need for SWCNTs, which can significantly enhance battery energy density and cycle life. Unlike tradition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom